Coulter Partners places Head of Manufacturing for Nanoform

Dr Rowe will be responsible for leading the manufacturing organization and for implementing the production criteria to guarantee best-in-class performance when producing nanonized APIs. His role will also ensure that efficient management systems are used to facilitate the fast delivery of project objectives for our customers.

Dr Rowe has extensive experience within the pharmaceutical industry, particularly in the field of particle engineering. In his most recent role as Particle Size Reduction Lead for GlaxoSmithKline, he was responsible for ensuring the efficient commercial manufacturability of new drug products developed through particle engineering. Dr Rowe has also held various technical and managerial roles within GlaxoSmithKline and Zeneca FCMO, and chaired several global particle size reduction forums.

The employment of a Head of Manufacturing coincides with the construction progress of Nanoform’s GMP manufacturing plant. The combination of strengthened manufacturing organization and increased capacity will enable Nanoform to achieve its aim of significantly increasing the number of drug compounds that reach clinical trials.

Edward Hæggström, CEO of Nanoform said: “It gives me great pleasure to welcome David as a Director of the company and part of the senior leadership team and I thank Coulter Partners once more for their professional support in achieving this quality appointment. David’s deep knowledge of particle engineering platforms and experience with industrial scale production will be extremely valuable as we continue to expand our manufacturing capacity.”

David Rowe added: “I am thrilled to be joining Nanoform. The company’s technical and academic pedigree is outstanding and has led to the development of a ground-breaking nanonization technology. I anticipate exciting times ahead and look forward to working with our partners to deliver innovative API physical properties that will benefit patients worldwide.”

About Nanoform

Nanoform Finland Limited is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.

For more information about Nanoform, please visit www.nanoform.fi